MC-4232: Phase II data

In the double-blind, placebo-controlled, Canadian Phase II MATCHED trial in 120 patients, MC-4232 (300 mg MC-1/20 mg lisinopril) met both the blood pressure and metabolic endpoints. Specifically, MC-4...